Cognizin Ingredient Shown to Improve Focus, Concentration and Memory

26 Jan 2011 --- A six-week study conducted at McLean Hospital, a Harvard Medical School affiliate located in Belmont, Mass., was designed to measure and visualize the functional effects of Cognizin on various facets of brain function.

1/26/2011 --- Deborah Yurgelun-Todd, Ph.D., Director of the Cognitive Neuroimaging Laboratory at The Brain Institute at The University of Utah, presented new scientific data on Kyowa Hakko's branded brain health ingredient Cognizin at the SupplySide Science Tour held January 24, 2011, in Irvine, Calif. She highlighted results of a six-week study conducted at McLean Hospital, a Harvard Medical School affiliate located in Belmont, Mass., designed to measure and visualize the functional effects of Cognizin on various facets of brain function.

On the first day of testing, 16 healthy subjects aged 40 - 60 years underwent functional Magnetic Resonance Imaging (fMRI) while completing both the Stroop task, which is designed to measure attention and reaction time, and the Morris Water Maze task, which examines spatial memory. Subjects were then given a daily oral dose of either 500 or 2000 mg of Cognizin for six weeks before a second imaging protocol was conducted.

After completion of the second fMRI imaging test, increased activation was seen during completion of the Stroop interference task. This was accompanied by improved accuracy in generating correct responses. 

These results indicated that use of Cognizin resulted in a better, more accurate performance, accompanied by increased brain metabolism. 
Increased activation was seen during completion of the second Water Maze test as well. This was accompanied by increased time spent in the correct quadrant. These results indicated that use of Cognizin resulted in better spatial memory retrieval, in addition to increased brain metabolism. Results were nearly identical for individuals receiving 500 mg and 2000 mg of Cognizin, confirming that statistically significant improvements in attention, focus, memory and recall can be achieved at dosing levels of 500 mg.

"Neuroimaging data demonstrated increased regional brain activation, which was related to increased concentration, greater ability to focus and improved accuracy on cognitive tasks after subjects received Cognizin," noted Dr. Yurgelun-Todd. "Greater performance on a spatial memory task was also observed."

Cognizin Citicoline is a natural, water-soluble brain health ingredient, and is a well-established part of the cognitive health category. Vast research indicates this safe and effective branded compound helps protect neural tissue from free radical damage. It also supports brain performance by enhancing metabolism and healthy activity. Unlike other single-action ingredients for brain health, Cognizin is multi-functional. It has shown to benefit individuals affected by memory loss, mood/behavioral disorders, mild cognitive impairment and certain vision disorders.

Related Articles

Nutrition & Health News

Diets rich in fish and vegetable oils could reduce epileptic seizures

18 Aug 2017 --- For the first time, production of estrogen in the brain has been directly linked to a study to the presence of docosahexaenoic acid (DHA). The findings of a Hiroshima University study could have implications for treating seizures, as it links DHA directly to a reduction in epileptic seizures.

Nutrition & Health News

Kyowa Hakko’s citicoline supplementation may slow glaucoma

18 Aug 2017 --- A 500mg dose of citicoline from Kyowa Hakko Europe (Kyowa) may significantly slow the progression of visual acuity loss due to glaucoma. This is according to a new study by researchers at the Sao Paolo Hospital Eye Clinic at the University of Milan, who followed 41 patients with progressing glaucoma – a disease that damages the optic nerve and can lead to vision problems and blindness – over two years.

Business News

DuPont expands US probiotics pilot facility to improve NPD, delivery times

18 Aug 2017 --- DuPont Nutrition & Health (DuPont) has announced a “substantial upgrade” to its probiotics pilot facility in Madison, Wisconsin, US. The new enhancements will increase its capability for rapidly developing and commercializing new probiotics with decreased time to market. The US$10 million investment allows for increased pace of new product development and significantly improved delivery times on pilot material for clinical trials and customer evaluations, according to DuPont.

Regulatory News

Cutting calories now “critical” to UK childhood obesity strategy

18 Aug 2017 --- The health agency Public Health England (PHE) has shifted its focus away from solely targeting sugar to cutting excess calorie consumption from all sources in its anti-obesity strategy for children in the UK. “A third of children leave primary school overweight or obese and an excess of calories – not just excess sugar consumption – is the root cause of this,” says Duncan Selbie, Chief Executive of PHE. “We will work with the food companies and retailers to tackle this as the next critical step in combating our childhood obesity problem.”

Nutrition & Health News

Walnuts activate brain area that controls appetite, finds study

17 Aug 2017 --- Consuming walnuts activates an area in the brain associated with regulating hunger and cravings. This is according to a first-of-its-kind new brain imaging study by researchers at Beth Israel Deaconess Medical Center (BIDMC), the findings of which, published online in the journal Diabetes, Obesity and Metabolism, reveal for the first time the neurocognitive impact the nuts have on the brain. 

More Articles
URL : http://www.nutritioninsight.com:80/news/Cognizin-Ingredient-Shown-to-Improve-Focus-Concentration-and-Memory.html